PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

Market Cap $71.73M Add to my watchlist

Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PAR	Cleansing Notice and Appendix 2A		16/04/20	451KB	Share
PAR	Reinstatement to Official Quotation	PRICE SENSITIVE	08/04/20	86.15KB	Share
PAR	Paradigm completes $35m raising	PRICE SENSITIVE	08/04/20	160.78KB	Share
PAR	Proposed issue of Securities - PAR		08/04/20	26.28KB	Share
PAR	PARADIGM TO HOST INVESTOR CALL		07/04/20	186.82KB	Share
PAR	Paradigm Reports Very Encouraging Real World Data	PRICE SENSITIVE	06/04/20	334.99KB	Share
PAR	Paradigm receives clarity on US regulatory pathway	PRICE SENSITIVE	06/04/20	212.2KB	Share
PAR	Paradigm Latest Corporate Presentation	PRICE SENSITIVE	06/04/20	4.61MB	Share
PAR	Voluntary Suspension	PRICE SENSITIVE	06/04/20	224.5KB	Share
PAR	Trading Halt	PRICE SENSITIVE	02/04/20	559.31KB	Share
PAR	Appendix 3G		24/03/20	371KB	Share
PAR	Paradigm to present at Virtual Conference, Friday 27th March		24/03/20	143.86KB	Share
PAR	All 10 participants in US FDA EAP have commenced treatment	PRICE SENSITIVE	24/03/20	280.06KB	Share
PAR	Change in substantial holding		16/03/20	208.44KB	Share
PAR	Change of Director's Interest Notice		16/03/20	161.2KB	Share
PAR	Appendix 3B and Appendix 3G		28/02/20	672.18KB	Share
PAR	Paradigm reports Positive Pre-IND meeting with US FDA	PRICE SENSITIVE	21/02/20	104.33KB	Share
PAR	Paradigm - first patient dosed in USA under FDA approved EAP	PRICE SENSITIVE	18/02/20	463.42KB	Share
PAR	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/20	618.72KB	Share
PAR	Paradigm presents MPS VI poster at WORLD Symposium	PRICE SENSITIVE	13/02/20	127.6KB	Share
PAR	Cleansing Notice and Appendix 2A		10/02/20	377.6KB	Share
PAR	Cleansing Notice and Appendix 2A		03/02/20	377.67KB	Share
PAR	Quarterly Update and Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	231.02KB	Share
PAR	Updated Appendix 2A		15/01/20	253.04KB	Share
PAR	Cleansing Notice		14/01/20	148.97KB	Share
PAR	Appendix 2A		14/01/20	252.93KB	Share
PAR	Cleansing Notice and Appendix 3B	PRICE SENSITIVE	18/12/19	690.74KB	Share
PAR	Cleansing Notice and Appendix 3B		13/12/19	404.6KB	Share
PAR	Paradigm End of Calendar Year Update	PRICE SENSITIVE	12/12/19	109.38KB	Share
PAR	Cleansing Notice		04/12/19	205.37KB	Share
PAR	Appendix 3B		04/12/19	426.46KB	Share
PAR	Cleansing Notice and Appendix 3B		25/11/19	397.52KB	Share
PAR	Change of Director's Interest Notice		19/11/19	176.76KB	Share
PAR	Change in substantial holding		14/11/19	193.39KB	Share
PAR	Change of Director's Interest Notice		14/11/19	161.28KB	Share
PAR	Cleansing Notice and Appendix 3B		11/11/19	396.78KB	Share
PAR	Results of Meeting		07/11/19	201.62KB	Share
PAR	Paradigm AGM Presentation	PRICE SENSITIVE	07/11/19	1.05MB	Share
PAR	Quarterly Update and Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	350.45KB	Share
PAR	PARADIGM PROVIDES REGULATORY FILING UPDATE	PRICE SENSITIVE	25/10/19	212.17KB	Share
PAR	Cleansing Notice and Appendix 3B		22/10/19	1.01MB	Share
PAR	Notice of Annual General Meeting/Proxy Form		04/10/19	376.19KB	Share
PAR	Cleansing Notice and Appendix 3B		01/10/19	854.94KB	Share
PAR	Osteoarthritis pain reduced by Paradigms Zilosul (PPS)	PRICE SENSITIVE	30/09/19	371.09KB	Share
PAR	Cleansing Notice and Appendix 3B		24/09/19	397.03KB	Share
PAR	Cleansing Notice and Appendix 3B		17/09/19	1.01MB	Share
PAR	Cleansing Notice and Appendix 3B		12/09/19	396.59KB	Share
PAR	PAR Expanded Access IND Cleared by US FDA	PRICE SENSITIVE	10/09/19	232.16KB	Share
PAR	Appendix 4G and 2019 Corporate Governance Statement		30/08/19	403.85KB	Share
PAR	Appendix 4E and 2019 Annual Report	PRICE SENSITIVE	30/08/19	1.12MB	Share
PAR	PARs drug reduces cartilage degradation in subjects with OA	PRICE SENSITIVE	29/08/19	1.19MB	Share
PAR	PARADIGM FILES FIRST IND WITH US FDA	PRICE SENSITIVE	07/08/19	146.39KB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	134.51KB	Share
PAR	Response to ASX Appendix 3Y Query		05/07/19	522.29KB	Share
PAR	Change of Director's Interest Notice		03/07/19	176.53KB	Share
PAR	Change in substantial holding		02/07/19	382.01KB	Share
PAR	Change of Director's Interest Notice		02/07/19	430.5KB	Share
PAR	Paradigm EOFY Update	PRICE SENSITIVE	28/06/19	326.67KB	Share
PAR	PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL	PRICE SENSITIVE	04/06/19	408.29KB	Share
PAR	PAR reports consistent pain reduction in knee OA of patients	PRICE SENSITIVE	28/05/19	352.81KB	Share
PAR	PAR CORRECTS AFR ARTICLE	PRICE SENSITIVE	21/05/19	83.76KB	Share
PAR	Updated Appendix 3B		13/05/19	428.13KB	Share
PAR	Appendix 3B		13/05/19	425.63KB	Share
PAR	Successful Completion of Retail Entitlement Offer	PRICE SENSITIVE	09/05/19	142.58KB	Share
PAR	Paradigm Corporate Update - May 2019	PRICE SENSITIVE	08/05/19	301.29KB	Share
PAR	Quarterly Report and Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	1.22MB	Share
PAR	Appendix 3B		26/04/19	279.04KB	Share
PAR	Cleansing Notice under section708A		26/04/19	404.13KB	Share
PAR	Completion of Institutional Entitlement Offer	PRICE SENSITIVE	24/04/19	161.84KB	Share
PAR	Cleansing statement under Section 708AA		24/04/19	156.1KB	Share
PAR	Change of Director's Interest Notice		23/04/19	474.6KB	Share
PAR	PAR Accelerated Non-Renounceable Rights Issue Offer Booklet	PRICE SENSITIVE	17/04/19	589.83KB	Share
PAR	Paradigm Confirms Capital Raise Commitments	PRICE SENSITIVE	17/04/19	104.96KB	Share
PAR	PARADIGM UPDATED CORPORATE PRESENTATION	PRICE SENSITIVE	15/04/19	1.93MB	Share
PAR	Appendix 3B		15/04/19	762.82KB	Share
PAR	PARADIGM LAUNCHES A$77.9M CAPITAL RAISE	PRICE SENSITIVE	15/04/19	100.11KB	Share
PAR	Cleansing statement under Section 708AA		15/04/19	223.23KB	Share
PAR	Trading Halt	PRICE SENSITIVE	15/04/19	463.2KB	Share
PAR	PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET	PRICE SENSITIVE	15/04/19	4.01MB	Share
PAR	Trading Halt	PRICE SENSITIVE	11/04/19	511.1KB	Share
PAR	Response to ASX Price Query	PRICE SENSITIVE	28/03/19	675.46KB	Share
PAR	Paradigm (PAR) Updated Investor Presentation	PRICE SENSITIVE	13/03/19	19.1MB	Share
PAR	Change of Director's Interest Notice		08/03/19	473.03KB	Share
PAR	S&P DJI Announces March 2019 Quarterly Rebalance	PRICE SENSITIVE	08/03/19	175.31KB	Share
PAR	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/19	384.01KB	Share
PAR	Cleansing Notice and Appendix 3B		14/02/19	953.72KB	Share
PAR	PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES	PRICE SENSITIVE	14/02/19	1.85MB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	423.18KB	Share
PAR	PARADIGMS SUPPLEMENTARY PHASE 2B DATA	PRICE SENSITIVE	20/12/18	812.37KB	Share
PAR	PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS	PRICE SENSITIVE	18/12/18	3.09MB	Share
PAR	PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL	PRICE SENSITIVE	18/12/18	576.83KB	Share
PAR	PAR - Conference Call Details - Phase 2b OA Results		17/12/18	176.21KB	Share
PAR	Trading Halt	PRICE SENSITIVE	14/12/18	505.17KB	Share
PAR	Change in substantial holding		13/12/18	154.21KB	Share
PAR	Change of Director's Interest Notice		13/12/18	430.61KB	Share
PAR	Appendix 3B and Cleansing Notice		13/12/18	952.71KB	Share
PAR	PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION	PRICE SENSITIVE	07/12/18	140.04KB	Share
PAR	Cleansing Notice and Appendix 3B		30/11/18	953.33KB	Share
PAR	Cleansing Notice and Appendix 3B		27/11/18	954.06KB	Share
PAR	Results of Meeting		26/11/18	118.78KB	Share

PAR Cleansing Notice and Appendix 2A
16/04/20		451KB	Share
PAR Reinstatement to Official Quotation
08/04/20	PRICE SENSITIVE	86.15KB	Share
PAR Paradigm completes $35m raising
08/04/20	PRICE SENSITIVE	160.78KB	Share
PAR Proposed issue of Securities - PAR
08/04/20		26.28KB	Share
PAR PARADIGM TO HOST INVESTOR CALL
07/04/20		186.82KB	Share
PAR Paradigm Reports Very Encouraging Real World Data
06/04/20	PRICE SENSITIVE	334.99KB	Share
PAR Paradigm receives clarity on US regulatory pathway
06/04/20	PRICE SENSITIVE	212.2KB	Share
PAR Paradigm Latest Corporate Presentation
06/04/20	PRICE SENSITIVE	4.61MB	Share
PAR Voluntary Suspension
06/04/20	PRICE SENSITIVE	224.5KB	Share
PAR Trading Halt
02/04/20	PRICE SENSITIVE	559.31KB	Share
PAR Appendix 3G
24/03/20		371KB	Share
PAR Paradigm to present at Virtual Conference, Friday 27th March
24/03/20		143.86KB	Share
PAR All 10 participants in US FDA EAP have commenced treatment
24/03/20	PRICE SENSITIVE	280.06KB	Share
PAR Change in substantial holding
16/03/20		208.44KB	Share
PAR Change of Director's Interest Notice
16/03/20		161.2KB	Share
PAR Appendix 3B and Appendix 3G
28/02/20		672.18KB	Share
PAR Paradigm reports Positive Pre-IND meeting with US FDA
21/02/20	PRICE SENSITIVE	104.33KB	Share
PAR Paradigm - first patient dosed in USA under FDA approved EAP
18/02/20	PRICE SENSITIVE	463.42KB	Share
PAR Half Yearly Report and Accounts
14/02/20	PRICE SENSITIVE	618.72KB	Share
PAR Paradigm presents MPS VI poster at WORLD Symposium
13/02/20	PRICE SENSITIVE	127.6KB	Share
PAR Cleansing Notice and Appendix 2A
10/02/20		377.6KB	Share
PAR Cleansing Notice and Appendix 2A
03/02/20		377.67KB	Share
PAR Quarterly Update and Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	231.02KB	Share
PAR Updated Appendix 2A
15/01/20		253.04KB	Share
PAR Cleansing Notice
14/01/20		148.97KB	Share
PAR Appendix 2A
14/01/20		252.93KB	Share
PAR Cleansing Notice and Appendix 3B
18/12/19	PRICE SENSITIVE	690.74KB	Share
PAR Cleansing Notice and Appendix 3B
13/12/19		404.6KB	Share
PAR Paradigm End of Calendar Year Update
12/12/19	PRICE SENSITIVE	109.38KB	Share
PAR Cleansing Notice
04/12/19		205.37KB	Share
PAR Appendix 3B
04/12/19		426.46KB	Share
PAR Cleansing Notice and Appendix 3B
25/11/19		397.52KB	Share
PAR Change of Director's Interest Notice
19/11/19		176.76KB	Share
PAR Change in substantial holding
14/11/19		193.39KB	Share
PAR Change of Director's Interest Notice
14/11/19		161.28KB	Share
PAR Cleansing Notice and Appendix 3B
11/11/19		396.78KB	Share
PAR Results of Meeting
07/11/19		201.62KB	Share
PAR Paradigm AGM Presentation
07/11/19	PRICE SENSITIVE	1.05MB	Share
PAR Quarterly Update and Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	350.45KB	Share
PAR PARADIGM PROVIDES REGULATORY FILING UPDATE
25/10/19	PRICE SENSITIVE	212.17KB	Share
PAR Cleansing Notice and Appendix 3B
22/10/19		1.01MB	Share
PAR Notice of Annual General Meeting/Proxy Form
04/10/19		376.19KB	Share
PAR Cleansing Notice and Appendix 3B
01/10/19		854.94KB	Share
PAR Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
30/09/19	PRICE SENSITIVE	371.09KB	Share
PAR Cleansing Notice and Appendix 3B
24/09/19		397.03KB	Share
PAR Cleansing Notice and Appendix 3B
17/09/19		1.01MB	Share
PAR Cleansing Notice and Appendix 3B
12/09/19		396.59KB	Share
PAR PAR Expanded Access IND Cleared by US FDA
10/09/19	PRICE SENSITIVE	232.16KB	Share
PAR Appendix 4G and 2019 Corporate Governance Statement
30/08/19		403.85KB	Share
PAR Appendix 4E and 2019 Annual Report
30/08/19	PRICE SENSITIVE	1.12MB	Share
PAR PARs drug reduces cartilage degradation in subjects with OA
29/08/19	PRICE SENSITIVE	1.19MB	Share
PAR PARADIGM FILES FIRST IND WITH US FDA
07/08/19	PRICE SENSITIVE	146.39KB	Share
PAR Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	134.51KB	Share
PAR Response to ASX Appendix 3Y Query
05/07/19		522.29KB	Share
PAR Change of Director's Interest Notice
03/07/19		176.53KB	Share
PAR Change in substantial holding
02/07/19		382.01KB	Share
PAR Change of Director's Interest Notice
02/07/19		430.5KB	Share
PAR Paradigm EOFY Update
28/06/19	PRICE SENSITIVE	326.67KB	Share
PAR PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL
04/06/19	PRICE SENSITIVE	408.29KB	Share
PAR PAR reports consistent pain reduction in knee OA of patients
28/05/19	PRICE SENSITIVE	352.81KB	Share
PAR PAR CORRECTS AFR ARTICLE
21/05/19	PRICE SENSITIVE	83.76KB	Share
PAR Updated Appendix 3B
13/05/19		428.13KB	Share
PAR Appendix 3B
13/05/19		425.63KB	Share
PAR Successful Completion of Retail Entitlement Offer
09/05/19	PRICE SENSITIVE	142.58KB	Share
PAR Paradigm Corporate Update - May 2019
08/05/19	PRICE SENSITIVE	301.29KB	Share
PAR Quarterly Report and Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	1.22MB	Share
PAR Appendix 3B
26/04/19		279.04KB	Share
PAR Cleansing Notice under section708A
26/04/19		404.13KB	Share
PAR Completion of Institutional Entitlement Offer
24/04/19	PRICE SENSITIVE	161.84KB	Share
PAR Cleansing statement under Section 708AA
24/04/19		156.1KB	Share
PAR Change of Director's Interest Notice
23/04/19		474.6KB	Share
PAR PAR Accelerated Non-Renounceable Rights Issue Offer Booklet
17/04/19	PRICE SENSITIVE	589.83KB	Share
PAR Paradigm Confirms Capital Raise Commitments
17/04/19	PRICE SENSITIVE	104.96KB	Share
PAR PARADIGM UPDATED CORPORATE PRESENTATION
15/04/19	PRICE SENSITIVE	1.93MB	Share
PAR Appendix 3B
15/04/19		762.82KB	Share
PAR PARADIGM LAUNCHES A$77.9M CAPITAL RAISE
15/04/19	PRICE SENSITIVE	100.11KB	Share
PAR Cleansing statement under Section 708AA
15/04/19		223.23KB	Share
PAR Trading Halt
15/04/19	PRICE SENSITIVE	463.2KB	Share
PAR PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET
15/04/19	PRICE SENSITIVE	4.01MB	Share
PAR Trading Halt
11/04/19	PRICE SENSITIVE	511.1KB	Share
PAR Response to ASX Price Query
28/03/19	PRICE SENSITIVE	675.46KB	Share
PAR Paradigm (PAR) Updated Investor Presentation
13/03/19	PRICE SENSITIVE	19.1MB	Share
PAR Change of Director's Interest Notice
08/03/19		473.03KB	Share
PAR S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19	PRICE SENSITIVE	175.31KB	Share
PAR Half Yearly Report and Accounts
21/02/19	PRICE SENSITIVE	384.01KB	Share
PAR Cleansing Notice and Appendix 3B
14/02/19		953.72KB	Share
PAR PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES
14/02/19	PRICE SENSITIVE	1.85MB	Share
PAR Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	423.18KB	Share
PAR PARADIGMS SUPPLEMENTARY PHASE 2B DATA
20/12/18	PRICE SENSITIVE	812.37KB	Share
PAR PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS
18/12/18	PRICE SENSITIVE	3.09MB	Share
PAR PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL
18/12/18	PRICE SENSITIVE	576.83KB	Share
PAR PAR - Conference Call Details - Phase 2b OA Results
17/12/18		176.21KB	Share
PAR Trading Halt
14/12/18	PRICE SENSITIVE	505.17KB	Share
PAR Change in substantial holding
13/12/18		154.21KB	Share
PAR Change of Director's Interest Notice
13/12/18		430.61KB	Share
PAR Appendix 3B and Cleansing Notice
13/12/18		952.71KB	Share
PAR PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION
07/12/18	PRICE SENSITIVE	140.04KB	Share
PAR Cleansing Notice and Appendix 3B
30/11/18		953.33KB	Share
PAR Cleansing Notice and Appendix 3B
27/11/18		954.06KB	Share
PAR Results of Meeting
26/11/18		118.78KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 20.5¢		Change -0.005(2.38%)		Mkt cap ! $71.73M

Open	High	Low	Value	Volume
20.0¢	21.0¢	20.0¢	$152.8K	744.7K

Buyers (Bids)

No.	Vol.	Price($)
3	78174	20.5¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	84426	5

View Market Depth

No.	Vol.	Price($)
2	76174	0.205
24	960353	0.200
14	520826	0.195
16	224370	0.190
9	185500	0.185

Price($)	Vol.	No.
0.210	84426	5
0.215	12111	2
0.220	112600	3
0.230	239296	4
0.235	27334	2

Last trade - 16.10pm 01/11/2024 (20 minute delay)


Last 20.5¢		Change -0.005 ( 0.15 %)
Open	High	Low	Volume
20.5¢	21.0¢	20.5¢	187251
Last updated 15.59pm 01/11/2024 ?

PAR (ASX) Chart

PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available